Zydus Lifesciences Q2 FY27 profit drops 26% to ₹925 crore; shares fall 4%
Synopsis
Zydus Lifesciences posted a 26.6% drop in net profit to ₹925.5 crore in Q2 FY27 even as revenue jumped 29% — a classic margin-squeeze story. With EBITDA margin nearly halving from 32.9% to 23.95% and R&D spending at 8.3% of revenue, rising costs are outpacing top-line momentum, sending shares down over 4%.
Key Takeaways
Zydus Lifesciences Q2 FY27 net profit fell 26.6 per cent year-on-year to ₹925.5 crore .
Revenue grew 29 per cent to ₹7,910 crore , up from ₹6,123 crore in Q2 FY26.
EBITDA margin compressed to 23.95 per cent from 32.9 per cent in the year-ago period.
North America formulations revenue rose 21 per cent year-on-year to ₹3,315 crore ($347 million in constant currency).
R&D investment stood at ₹657.3 crore , or 8.3 per cent of revenue.
Shares fell as much as 4.59 per cent intraday to ₹1,182.05 before recovering partially to ₹1,201.55 .
Zydus Lifesciences on Wednesday, 4 November 2026 reported a 26.6 per cent year-on-year decline in consolidated net profit to ₹925.5 crore for the July–September quarter of FY27, down from approximately ₹1,261 crore in the same period last year. The sharp profit fall sent shares tumbling even as the company posted strong top-line growth.
Revenue Grows, But Margins Compress
Despite the profit slide, Zydus Lifesciences revenue surged 29 per cent year-on-year to ₹7,910 crore in Q2 FY27, compared to ₹6,123 crore in the year-ago quarter. However, EBITDA slipped 6 per cent to ₹1,895 crore from ₹2,015 crore, and the EBITDA margin contracted sharply to 23.95 per cent from 32.9 per cent in Q2 FY26. The divergence between revenue growth and profit decline points to significantly higher costs eating into earnings during the quarter.
Key Business Segments
India formulations revenue came in at ₹1,884 crore, up 18 per cent year-on-year, accounting for 24 per cent of consolidated revenue, with branded formulations growing 19 per cent. The North America formulations business was the standout segment, posting revenue of ₹3,315 crore, up 21 per cent year-on-year and 7 per cent quarter-on-quarter, driven by volume expansion in the base business and scale-up of the US speciality portfolio. In constant currency terms, North America revenue stood at $347 million.
International markets formulation revenue rose 33 per cent year-on-year to ₹1,001 crore. The API business posted modest revenue of ₹149 crore, up just 1 per cent. Notably, the Alliances and Others segment surged 374 per cent to ₹59.2 crore, though off a low base.
R&D and Capital Expenditure
The company's research and development (R&D) investment for the quarter stood at ₹657.3 crore, representing 8.3 per cent of revenue — a signal of continued pipeline investment. Organic capital expenditure was ₹465.5 crore during the period. The elevated R&D spending, while indicative of long-term intent, is a key factor compressing near-term margins.
Market Reaction
Shares of Zydus Lifesciences reacted sharply to the earnings release on Wednesday, hitting an intraday low with a decline of 4.59 per cent to ₹1,182.05 around 2 pm IST. The stock later pared some losses to trade at ₹1,201.55, down approximately 3 per cent. The counter has a 52-week high of ₹1,266.15 and a 52-week low of ₹835.85. This comes amid broader investor scrutiny of pharma earnings where margin pressure has become a recurring theme in recent quarters.
Point of View
910 crore is impressive, but an EBITDA margin nearly nine percentage points below last year's level suggests that expansion — particularly in the US speciality business — is coming at a steep cost. The R&D spend of 8.3% of revenue is above the sector average and reflects a strategic long-term bet, but investors are pricing in near-term earnings risk today. The real question for the next two quarters is whether US speciality scale-up revenues can grow fast enough to offset the structural cost overhang — and whether the broader pharma sector's margin compression narrative is temporary or the new normal.
NationPress
4 Nov 2026
Frequently Asked Questions
Why did Zydus Lifesciences' net profit fall in Q2 FY27?
Zydus Lifesciences' consolidated net profit fell 26.6 per cent year-on-year to ₹925.5 crore in Q2 FY27 primarily due to margin compression, with EBITDA margin declining sharply to 23.95 per cent from 32.9 per cent in the same period last year. Higher costs related to R&D spending (₹657.3 crore, or 8.3% of revenue) and capital expenditure (₹465.5 crore) are key factors squeezing profitability despite strong revenue growth.
How did Zydus Lifesciences' revenue perform in Q2 FY27?
Revenue grew 29 per cent year-on-year to ₹7,910 crore in Q2 FY27, up from ₹6,123 crore in Q2 FY26. North America formulations was the largest contributor at ₹3,315 crore, while India formulations added ₹1,884 crore and international markets contributed ₹1,001 crore.
How did Zydus Lifesciences shares react to Q2 results?
Shares of Zydus Lifesciences fell as much as 4.59 per cent intraday to ₹1,182.05 on Wednesday following the earnings release, before paring losses to trade at approximately ₹1,201.55, down around 3 per cent. The stock's 52-week high is ₹1,266.15 and its 52-week low is ₹835.85.
How did Zydus Lifesciences' North America business perform?
North America formulations posted revenue of ₹3,315 crore in Q2 FY27, up 21 per cent year-on-year and 7 per cent quarter-on-quarter, driven by volume expansion in the base business and scale-up of the US speciality portfolio. In constant currency terms, North America revenue stood at $347 million.
What was Zydus Lifesciences' EBITDA and margin in Q2 FY27?
EBITDA for Q2 FY27 came in at ₹1,895 crore, down 6 per cent from ₹2,015 crore in the year-ago period. The EBITDA margin contracted significantly to 23.95 per cent from 32.9 per cent in Q2 FY26, reflecting higher operating costs relative to revenue.
